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Local bacteria affect the efficacy of 
chemotherapeutic drugs
Panos Lehouritis1, Joanne Cummins1, Michael Stanton1, Carola T. Murphy1, 
Florence O. McCarthy2, Gregor Reid3,4, Camilla Urbaniak3,4, William L. Byrne1 & 
Mark Tangney1
In this study, the potential effects of bacteria on the efficacy of frequently used chemotherapies 
was examined. Bacteria and cancer cell lines were examined in vitro and in vivo for changes in 
the efficacy of cancer cell killing mediated by chemotherapeutic agents. Of 30 drugs examined in 
vitro, the efficacy of 10 was found to be significantly inhibited by certain bacteria, while the same 
bacteria improved the efficacy of six others. HPLC and mass spectrometry analyses of sample drugs 
(gemcitabine, fludarabine, cladribine, CB1954) demonstrated modification of drug chemical structure. 
The chemoresistance or increased cytotoxicity observed in vitro with sample drugs (gemcitabine and 
CB1954) was replicated in in vivo murine subcutaneous tumour models. These findings suggest that 
bacterial presence in the body due to systemic or local infection may influence tumour responses or 
off-target toxicity during chemotherapy.
Tumour responses to chemotherapy vary, and deeper insight into the reasons for therapeutic failure 
with certain tumours while other apparently similar tumours respond well, stands to guide and improve 
existing therapeutic regimes, while informing the development of new treatments. Bacteria have been 
linked with various cancers in a number of ways1. For example, local bacterial-induced inflammation has 
been linked with cancer promotion and progression, via indirect distal effects from the gastro intestinal 
tract (GIT) microbiome, or directly such as in the case of Helicobacter pylori2,3. Recent research in exper-
imental tumours has revealed that gut bacteria may influence the outcome of chemotherapy indirectly 
via influencing the immune system4,5. For decades, naturally occurring bacteria of different types have 
been isolated from patient tumours of various histological types1. In parallel to this, it is well known that 
deliberate systemic administration of bacteria to animals or patients results in selective replication within 
solid tumours6–9. Recently, we and others have characterised the bacterial populations naturally present 
within malignant and non-malignant tissue of the breast10. We have reported the presence of a range of 
bacteria in the breast tissue of cancer patients, while Xuan et al. reported similar findings in breast cancer 
patients, and suggested differences in the types of bacteria present in malignant versus non-malignant 
adjacent breast tissue10,11. Others have shown that bacteria such as E. coli and Fusobacterium are associ-
ated with colorectal cancer12–14.
Bacteria have the capacity to transform organic chemicals, such as nutrients, pollutants, toxins, drugs 
and other organic molecules, via endogenous enzymes, and this is exemplified in the field of industrial 
biotransformation in which various bacteria are used to chemically modify non-biological organic mol-
ecules15,16. Conceivably, there is potential for direct interaction between systemically administered drugs 
at various body sites in the course of infection or in the case of orally administered drugs and microbi-
ota of the small intestine. So far, the effects of in situ bacterial biotransformation of chemotherapeutics, 
during cancer therapy have not been examined thoroughly. We sought to investigate if bacteria have the 
potential to influence the efficacy of small drug chemotherapeutics.
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Results
In vitro assay design and validation. Various bacteria and cancer cell lines were examined in vitro 
for changes in the efficacy of cancer cell killing mediated by a range of chemotherapeutic agents. An in 
vitro assay was developed to facilitate drug and bacteria screening as described in experimental proce-
dures and Fig. S1. Based on previously reported microbial analysis of tissue and tumour10,11 as well as our 
own observations (Fig. S2) we chose to use E. coli as our main drug-testing agent, in addition to Listeria 
welshimeri (see below). Assay validation proceeded with several drugs whose effects were observed to 
be altered in the presence of E. coli. A drug whose efficacy was enhanced (Fig. 1a—AQ4N), and a drug 
whose efficacy was decreased (Fig. 1b—gemcitabine) by E. coli were examined with a range of bacterial 
concentrations. In both cases, a dose response (P < 0.01) was achieved using three different bacterial 
concentrations, indicating that changes in drug cytotoxicity were originating from the bacteria. A dose 
response using different drug concentrations (P < 0.01) was also demonstrated with the drug tegafur and 
CB1954 (Fig. 1c,d).
In order to investigate if the observed effects were mediated by biochemical modification of the drugs, 
rather than any physical bacterial drug absorption (e.g. in the case of gemcitabine), the in vitro assay 
was performed with bacteria treated in a number of ways prior to incubation with drug. Gemcitabine 
was examined with supernatant from E. coli which had been lysed by sonication. Similar decreases 
in cytotoxicity were observed when gemcitabine was incubated with this lysate as with intact bacteria 
(Fig.  1e,f). Upon heat-inactivation of the lysate (or intact bacteria), no reduction in cytotoxicity was 
evident (P < 0.001), suggesting the involvement of enzymatic activity.
Effects of bacteria on chemotherapeutic drug cytotoxicity in vitro. Studies proceeded with 
bacterial strains representing frequently occurring bacterial species in patient tumours; Gram-negative 
non-pathogenic E. coli and Gram-positive Listeria welshimeri (also non-pathogenic)10,11; Fig. S2. 
Thirty agents from a number of different drug classes were examined, the majority of which represent 
commonly-employed FDA-licenced drugs. The results are summarised in Table  1. Of 30 drugs exam-
ined, the cancer killing efficacies of 10 were found to be decreased, while in general the same bacteria 
increased the efficacies of 6 others. 14 drugs did not display any difference in efficacy following bacteria 
co-incubation. Observed effects on drug cytotoxicity were not identical between E. coli and L. welshimeri 
(where tested), with E. coli increasing the effect of tegafur (unlike L. welshimeri), and decreasing the effect 
of vidarabine, gemcitabine and etoposide phosphate (unlike L. welshimeri).
HPLC and mass spectrometry analyses. These findings prompted us to analyse a number of sam-
ple drugs to elucidate further the basis of drug alteration using HPLC and Mass Spectrometry. All of the 
drugs tested produced new chromatogram peaks in the presence of bacteria indicating that they were all 
biotransformed (Fig. 2). Further analysis of each peak by Mass Spectrometry revealed that gemcitabine 
was biotransformed to a new mass of 306 m/z, (4.65 min) consistent with the formula C9H11N3O4F2 sug-
gesting acetylation. Fludarabine and cladribine produced new masses of 154 m/z at 4.42 min (C5H5N5F) 
and 170 m/z at 5.42 min (C5H5N5Cl35) respectively, consistent with an enzymatic hydrolysis of the nucle-
oside’s glycosidic bond yielding the halogenated purine bases. CB1954 (13.45 min) also produced a new 
peak at 8.47 min in the presence of bacteria which upon further inspection resolved to two mass spec-
trometry peaks: 239 m/z and 223 m/z equivalent to the published hydroxylamine and amine derivatives 
that are associated with a CB1954 reduction reaction17 (see Fig. 3 for the theoretical molecular structure 
of the new derivatives).
Murine models of intratumoural bacterial effects on chemotherapy. Our lab has previously 
shown the ability of E. coli and other bacterial species to selectively replicate in tumours over time in 
various murine models18,19. In this study, we initially validated the growth of E. coli in CT26 tumours 
following intratumoural (i.t.) administration (Fig. S4). The chemoresistance observed in vitro (Fig. S3) 
with a sample drug (gemicitabine) was examined in this model. Mice bearing CT26 tumours were i.t. 
injected with E. coli or PBS, and intraperitoneally (i.p.) injected with gemcitabine or PBS and moni-
tored over time (Fig. 4). As expected, the PBS:PBS and Bacteria:PBS groups showed the greatest tumour 
volumes over time. Significantly increased tumour volume was observed in the gemcitabine + bacteria 
group compared with the gemcitabine alone group at various time points (P < 0.03; Fig. 4a). Survival was 
significantly reduced in the gemcitabine + bacteria group compared with the gemcitabine alone group 
(17 days vs. 28 days + /− 1.25; P = 0.004; Fig. 4b). These data indicate reduced gemcitabine anti-tumour 
activity in tumours containing bacteria. Bacteria alone did not significantly affect tumour volume relative 
to PBS administration (P > 0.2), although some reduction is evident in bacteria administered tumours, 
suggesting that the reduced gemcitabine effect may be partially masked.
The ability of the same bacterial species to activate the cytotoxicity of another drug, CB1954, was also 
examined in this model. A significant increase in median survival (26 days vs. 8 days. P = 0.028) was 
observed in the CB1954 + bacteria group compared with the CB1954 alone group (Fig.  5), indicating 
drug activation by the intratumoral bacteria.
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Figure 1. Tumour Cell Survival. Cell survival assay. (a) E.coli at different cfu/ml were co-incubated 
with AQ4N (10 μ M) after which the supernatant was applied directly to LLC cells (P < 0.01). (b) E. coli 
at different cfu/ml were co-incubated with gemcitabine (10 μ M) after which the supernatant was directly 
applied to 4T1 Luc cells (P < 0.01). E.coli was co-incubated with Tegafur (c) or CB1954 (d) at the indicated 
concentrations after which the supernatant was directly applied to TRAMPC1 cells or CT26 (P < 0.01). Data 
(a–f) represent the average and standard error of four technical replicates. Data shown are representative 
of 3 independent experiments. (e) Tumour cell survival assay stained with MTS. Gemcitabine (10 μ M) was 
incubated with live or heat killed E. coli (P < 0.001). (f) Tumour cell survival assay. Gemcitabine (10 μ M) 
was incubated with either bacterial lysate (equivalent amounts to cell survival assay live bacteria dosages) 
alone or bacterial lysate that has been heat inactivated (P < 0.001). Data represent the average and standard 
error of four technical replicates. Data shown are representative of 2 independent experiments.
www.nature.com/scientificreports/
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Discussion
In this work we examined the ability of wild type bacterial species encountered in the body to influence 
the efficacy of popular chemotherapeutic drugs that are administered to patients undergoing treatment 
in the hope of broadening our understanding of bacteria-drug interactions. It is well known that the 
human body has its own microbiome which differs from one individual to another, with the majority 
of available information confined to ‘tract’-related body regions20,21, but also recently placenta, a unique 
tissue type sharing many features with tumours22. Recent data presented by Xuan and co-workers11 and 
our group10 describe a multitude of different bacteria taxa living naturally within breast tumours and in 
the surrounding healthy tissue. The ability of bacteria to opportunistically proliferate or induce infec-
tions within tumours of cancer patients has been a sporadic diachronic phenomenon which dates as far 
back as 200 years23. For example, in 1926 Glover stated that certain bacteria were consistently isolated 
from neoplastic tissue24. Between the years 1936–1955 several publications reported that microbes were 
present in cancer tissue1 (it was observations similar to those that ignited interest in using bacteria 
as anticancer agents leading to the development of Bacillus Calmette-Guérin (BCG) as treatment for 
bladder cancer25). Previous publications detailing sequence analyses of tissue from patients with breast 
cancer demonstrated the presence of many species, of which proteobacteria dominated followed by fermi-
cutes10,11. Furthermore, tissue colonisation as a consequence of cancer chemotherapy is known to occur 
by antibiotic resistant bacteria26.
Drug Name Drug Class
Cytotoxicity
E. coli L. welshimeri
Tegafur Anti-metabolite Up NC
Fludarabine de phosphate Anti-metabolite Up Up
Capecitabine Anti-metabolite NC NC
5-fluorocytosine Anti-metabolite Up NC
5-fluorouracil Anti-metabolite NC NC
6-Mercaptopurine-2′ -deoxyriboside Anti-metabolite Up n/d
Pentostatin Anti-metabolite NC NC
Cytarabine Anti-metabolite NC NC
Clofarabine Anti-metabolite NC NC
Cladribine Anti-metabolite Down Down
Valacyclovir Anti-metabolite NC n/d
Ara G hydrate Anti-metabolite NC NC
Nelarabine Anti-metabolite NC NC
Vidarabine Anti-metabolite Down NC
Gemcitabine Anti-metabolite Down NC
Doxorubicin Anti-tumour Antibiotics Down n/d
Daunorubicin Anti-tumour Antibiotics Down Down
Vinblastine Anti-tumour Antibiotics NC n/d
Actinomycin Anti-tumour Antibiotics NC n/d
Idarubicin Anti-tumour Antibiotics Down n/d
Mitomycin C Anti-tumour Antibiotics NC n/d
Streptonegrin Anti-tumour Antibiotics NC n/d
Etoposide phosphate Topo Isomerase Inhibitor Down NC
Irinotecan Topo Isomerase Inhibitor NC NC
AQ4N Topo Isomerase Inhibitor Up n/d
Mitoxantrone Topo Isomerase Inhibitor Down n/d
Β -Lapachone Topo Isomerase Inhibitor Down n/d
Estramustine Alkylating Agent NC n/d
CB1954 Alkylating Agent Up Up
Menadione Reactive oxygen generator Down n/d
Table 1.  Summary of observations from in vitro cytotoxicity screen of drugs with bacteria using the 
bacterial cell kill assay. n/d = not determined, NC = No Change.
www.nature.com/scientificreports/
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As we reproduced similar results to Xuan and co-workers11 (Fig. S2), we chose E. coli (a proteo-
bacterium) and Listeria welshimeri (a fermicute) for our studies, because of practical reasons but also 
because they represent a Gram-negative and a Gram-positive species respectively which have dissimilar 
outer membranes and metabolism making them attractive for comparative drug studies. Most of the 
current drug arsenal is composed of small molecular weight organic molecules which are subject to 
biotransformation (enzymatic modification or degradation) by different tissue enzymes (e.g. cytochrome 
P45027). However, biotransformations can also originate from bacteria which have their own unique 
‘enzymolome’.
Figure 2. HPLC analysis of drug biotransformations. Chromatograms: (a) Top; Vehicle alone (PBS DMSO 
0.1%), Bottom; E. coli alone (b) Top; Gemcitabine, Bottom; Gemcitabine and E. coli. (c) Top; Fludarabine, 
Bottom; Fludarabine and E. coli (d) Top; Cladribine, Bottom; E. coli and Fludarabine. (e) Top; CB1954, 
Bottom; E. coli and CB1954 The drugs and their derivatives were detected by UV absorbance at 254 nm.
www.nature.com/scientificreports/
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Initial assay tests were performed with E. coli and gemcitabine, AQ4N, tegafur and CB1954 (Fig. 1). 
Dose responses were achieved with both bacteria and drug as shown in Fig.  1(a–d) and these results 
validated our in vitro assay. While the levels of bacteria used in this assay were arbitrary, such bacterial 
numbers are not unrealistic in clinical settings28. The cumulative data indicate that the effects observed 
were direct consequences of enzymatic biotransformation. Analysis of gemcitabine suggested that bacte-
rial enzyme(s) was responsible for rescuing cells from its toxic effects as both heat inactivated bacteria or 
bacteria lysates failed to protect cancer cells in its presence (Fig. 1e,f). Notably, no significant tumour cell 
death was observed in vitro following incubation with supernatant from live or lysed bacteria cells alone 
suggesting that there is no cytotoxicity arising from any internal toxic metabolite of E. coli (Fig. 1e,f).
H 
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Figure 3. Schematic of drugs and proposed derivatives. Structure prediction of drugs and derivatives 
based on mass spectrometry analysis. Hypothetical illustrations of structures based on elemental 
composition analysis and atomic mass fitting of HPLC peaks of drugs or drug derivatives after co-incubation 
with bacteria. For each molecule, its empirical formula and mass to charge ratio is also shown.
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We decided to screen a panel of drugs which are indicated for various cancers, that would be large 
enough to cover multiple drug classes to get a better view of the drug modification landscape. However, 
certain drugs although popular, were omitted from this screen. For example, drugs such as cyclophos-
phamide, ifosfamide, vinorelbine and vincristine would require a P450 enzyme for modification which is 
absent in E. coli and Listeria welshimeri29,30; the latter also lack the enzyme Carboxypeptidase G2 which 
is required to degrade pemetrexed31; taxanes were unlikely to be modified by our strains as they are 
artificially produced in bacteria to begin with32; finally, drugs such as cisplatin which have an inorganic 
structure were also omitted. The drug screening was performed in different cell lines where we tested 
each drug and scored only cases in which we observed a difference between bacteria/drug alone or in 
combination (Table 1).
The cytotoxicities of approximately 20% of the drugs tested were increased, 30% were decreased and 
50% were unaffected. The cytotoxicities of cladribine, vidarabine and gemcitabine and other popular drugs 
like etoposide phosphate and anti-cancer antibiotics like doxorubicin were decreased by bacteria. The 
majority of drugs were not affected by the presence of bacteria in our assays, at least at the concentrations 
examined. The finding that bacteria activated fludarabine and 6-mercaptopurine-2-deoxyadenosine was 
not surprising. In viral vector-based gene therapy, the enzyme purine nucleoside phosphorylase (PNP) 
has been used to activate fludarabine when expressed by cancer cells following viral vector delivery33. 
However, the productive interaction of bacteria with a drug in the context of our thesis is a complicated 
process which may involve both cytoplasmic enzymes and cell membrane transporters before and after 
a drug’s biotransformation. It may be more relevant to consider a bacterial cell as a reservoir of disparate 
enzymes or as a biotransformational monad. In agreement with our observations, Chen et al.34 showed 
that Salmonella can activate the nucleoside 6-methylpurine-2-deoxyadenosine to 6-methylpurine, a cyto-
toxic agent, intriguingly, despite the fact that fludarabine, vidarabine and cladribine have very similar 
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Figure 4. E. coli decreases the efficacy of gemcitabine in vivo. Subcutaneous flank CT26 tumours 
growing in Balb/c mice were injected i.t with bacteria or PBS vehicle alone. Gemcitabine (60 mg/kg) was 
injected i.p. five times at three day intervals. (a) Tumour volume (%) relative to the first day of gemcitabine 
injection (day 0) is shown. *P < 0.03, **P = 0.002 (Bonferroni post hoc test) for gemcitabine alone versus 
gemcitabine + bacteria. (b) Kaplan-Meier plots showing mouse survival over time. The median survival post 
Day 0 of the gemcitabine + bacteria group was significantly less than that of the gemcitabine alone group 
(17 days vs. 28 days + /− 1.25; P = 0.008). Data are expressed as mean ± SEM of 4 to 8 individual mice per 
group.
www.nature.com/scientificreports/
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structures, incubation with bacteria produced opposing effects on cytotoxicity. Similarly, we observed 
opposite effects with AQ4N (banoxantrone) and its analogue mitoxantrone (Table  1). Consistent with 
this, Westman et al.35 also reported that doxorubicin can be biotransformed by Streptomyces cell extracts 
via deglycosylation by NADH dehydrogenase.
In order to gain a molecular insight, we analysed the products of gemcitabine and E. coli by HPLC and 
mass spectrometry and discovered that a new extra peak appeared in the chromatogram which eluted 
later than gemcitabine (Fig. 2). This new peak had a molecular ion of 306 m/z which indicated that bio-
transformation had indeed taken place, consistent with a theoretical acetylation at the nitrogen atom of 
the amine group on the molecule’s base (Fig. 3). However, further molecular analysis would be required 
to confirm this. The hydrolysis of fludarabine/cladribine to their purine base was not as surprising to 
witness. Such a reaction is known to be mediated by the isolated enzyme PNP in various gene therapy 
settings36. However, to our knowledge, a productive, direct interaction of live E. coli/ Listeria welshimeri 
with these nucleosides in the context presented in this study (live cell biotransformation and influence of 
efficacy) has not been reported to date. Especially interesting was the fact that bacteria could hydrolyse 
cladribine to its chlorinated purine base, but in contrast to fludarabine, they rendered it ineffective (this 
is also interesting as cladribine is now in clinical trials as an oral drug for multiple sclerosis37) The precise 
molecular mechanism for this difference is currently unknown, but it is relevant to draw attention to 
the fact that all the therapeutic nucleosides become activated intracellular38 so it may be that an extra-
cellular activation of cladribine by E. coli along with residual free enzymes from dead bacteria, disables 
its therapeutic potential. The reduction of CB1954 to its two canonical derivatives shown in Fig. 3 was 
not a surprise and although this nitroreduction reaction is known to occur, the ability of Gram-positive 
and negative genetically unmodified bacteria to turn over the prodrug and mediate cell killing has not 
been shown before. From our screen it becomes apparent that bacteria have the capacity to influence 
the therapeutic effects of both drugs (e.g. gemcitabine) or prodrugs (e.g. cladribine). The biochemical 
events which follow after drug activation leading to cell death or drug deactivation are beyond the scope 
of this project.
We replicated our in vitro observations in an experimental mouse model where we demonstrated 
that bacteria can hamper the effects of a selected drug, focussing on the drug gemcitabine because of its 
popularity as an anticancer agent and due to our interesting counterintuitive finding that bacteria can 
neutralise its toxicity. We acknowledge that such a model is quite artificial compared with clinical reality 
but it provides proof of principle. Nonetheless, it was apparent from the murine data that a growing in 
vivo tumour supports bacterial growth and provides the environment to permit the effects on a sample 
Figure 5. E. coli increases the cytotoxicity of CB1954. Subcutaneous flank CT26 tumours growing in 
Balb/c mice were injected i.t with bacteria or PBS vehicle alone. CB1954 (20 mg/kg) was injected i.p. for the 
duration of the experiment at 3 day intervals. (a) Tumour volume (%) relative to the first day of CB1954 
injection (day 0) is shown. (b) Kaplan-Meier plots showing mouse survival over time. The median survival 
post Day 0 of the CB1954 + bacteria group was significantly greater than that of the CB1954 alone group (26 
days vs. 8 days. P = 0.0374). Data are expressed as mean ± SEM of 3-5 individual mice per group.
www.nature.com/scientificreports/
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drug as per the in vitro assay (Fig.  4). We further recapitulated the in vitro cytotoxicity data from an 
activating drug (CB1954) in this in vivo model (Fig. 5). The in vitro (Fig. 1) and in vivo data with both 
drugs examined (in which E. coli has opposing effects) are consistent.
Research in this context has primarily focused on the ability of gut microorganisms to affect the 
metabolism of pharmaceutical agents (reviewed in39,40). One of the most popular cases studied has been 
the anti-cancer agent irinotecan and its toxic GIT side effects41. The gut bacterium Eggerthella lenta 
deactivates the cardiac drug digoxin influencing its concentration in body fluids40. Our findings take the 
field of microbial-drug interaction a step further, away from the GIT. We have shown that the types of 
bacteria found in tumours may influence tumour responses to certain chemotherapeutic drugs, either 
positively or negatively, depending on the characteristics of the infection (different bacteria produced 
different effects e.g. E. coli affected more drugs than Listeria). Notionally, drugs can encounter bacteria 
at different parts of the body (i.e. an infectious focus) in different settings resulting in in situ biotrans-
formation. Although bacterial infections do not occur frequently, they are by far not clinically irrelevant: 
for example, infections of the skin are common42 and could induce local skin toxicity if they came in 
contact with a drug that can be activated to a more toxic form, infections of the stomach by H. pylori 
are common43 and can result in the breakdown of L-DOPA (used to treat Parkinson’s disease) affecting 
its bioavailability44; monomicrobial or polymicrobial infections of tissues can arise from blood or solid 
tumours44; bacteraemia due to solid tumours can also present itself in cancer patients45 and infections of 
pleural effusions are not uncommon in thoracic disease of neoplastic origin46. Chemotherapy itself has 
also been associated with increased bacterial infection47.
Our findings are also pertinent to alternative anti-cancer strategies that are emerging which inves-
tigate combinations of chemotherapy and bacteria to treat solid tumours. Specifically, our work could 
interest groups working with the clinically approved anti-cancer bacterium BCG which is used to treat 
bladder cancer25. Chemotherapy is used post BCG treatments48 or in combination with BCG49. In addi-
tion to this, early experimental systems that investigate the use of chemotherapy in conjunction with 
bacteria (Gram-positive or Gram-negative strains)50,51 should also be aware of potential biochemical drug 
interactions with their agent’s enzymolome.
In conclusion, our data bring attention to the fact that internal bacteria can interact with a drug ther-
apy and could under certain circumstances influence treatment efficacy and/or side effects.
Conclusions
Our results show that live wild type bacteria with natural enzyme levels can affect the efficacy of some 
anticancer agents either positively or negatively in vitro and in vivo, most likely via enzymatic modifi-
cations. Our findings indicate the potential for local or systemic bacterial infections to act as an in situ 
biotransforming reservoirs which may complicate cancer therapy, through reducing anti-tumour efficacy 
or increasing off-target toxicity. For drugs whose cytotoxicity is increased by bacteria, our data also sup-
port the potential to improve therapeutic index through deliberate modification of the bacterial content 
of cancer patients or tumours.
Materials and Methods
Bacteria and cell lines. E. coli Nissle 1917 (UCC culture collection) was cultivated aerobically in 
L-Broth or L-Agar (Sigma) at 37 °C. Bioluminescent E. coli was described by us previously18 and cultured 
in the presence of 300 mg/ml erythromycin. Listeria welshimeri Serovar 6B SLCC5334 was purchased 
from ECACC and cultivated at 37 °C in Brain Heart Infusion (BHI) medium. The E. coli nitroreductase 
triple deletion mutant and its parent strain were kindly provided by Dr Antonio Valle52. Lewis Lung 
Carcinoma (LLC), 4T1 (mouse mammary carcinoma) and CT26 (mouse colorectal carcinoma) cells were 
purchased from ATCC and were propagated according to the supplier’s instructions. The murine recycled 
prostate cancer cell line TRAMPC1 was kindly provided by Ciavarra RP53 of Eastern Virginia Medical 
School, Norfolk USA, and propagated as described in54.
Drugs. All drugs and enzymes were purchased from Sigma except: Etoposide Phosphate (Santa Cruz), 
Capecitabine (Santa Cruz), AQ4N (R&D), Nelarabine (A&B), and Vidarabine (Santa Cruz). Drugs were 
resuspended in H2O or DMSO, with appropriate control vehicle utilised accordingly in all experiments.
Cell cytotoxicity assay. Microtitre plates (96-well) were pre-seeded with 4000 cells/well in appro-
priate medium for each cell line and allowed to attach overnight. On the day of the assay, bacteria were 
cultured to log-phase and a subculture ratio, corresponding to an OD600nm of 0.2 determined for each 
strain, was exposed for 2 h (4 h in the case of IC50s) to drug in falcon tubes containing DMEM in a tissue 
culture incubator. Falcon content was filter-sterilized to remove presence of bacteria (using 0.2 μ m pore 
filters (Starsted) before adding 200 μ l per well. Plates were incubated until cells in control (untreated) 
had achieved confluent growth. Cytotoxicity was quantified using an MTS staining with the Cell Titre 
96 AQueous One solution Cell Proliferation Assay (Promega). The plates were incubated with normal 
media (80 μ l) and MTS solution (20 μ l) in a 37 °C incubator for approximately 2 h (until distinct change 
of colour occurred).
www.nature.com/scientificreports/
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Bacterial lysis and heat inactivation. Bacteria were heat inactivated at 95 °C for 40 min. Lysis was 
facilitated by sonication using three 10 sec pulses (at 20 Kz, 50 W). Between each pulse, samples were 
incubated on ice for 30 seconds. A 20-fold drop in optical density was considered sufficient lysis.
HPLC and Mass spectrometry analyses. Sample preparation. Bacteria were grown to an OD600 
between 0.8 and 1 in appropriate media. The bacteria were washed once in PBS and then resuspended in 
the same volume of PBS. The drugs Fludarabine, Cladribine and Gemcitabine were dissolved in DMSO 
(100 mM) and were added to the bacterial sample to give a final concentration of Fludarabine 10 μ M, 
Cladribine 10 μ M and Gemcitabine 1 mM. Bacteria and drug were incubated for 1 h at 37 °C, and centri-
fuged at 13,500 rpm for 5 min. Supernatant containing drug was transferred to a spin filtration column 
with a MWCO of 3000 (Vivaspin) and further centrifuged for 10 min at 13500 rpm. Samples were kept 
on ice before HPLC analysis.
HPLC and Mass spectrometry analysis. The results described were obtained using a Waters Micromass 
LCT Premier mass spectrometer (Instrument number KD160). Analysis was performed in ESI + mode 
using a gradient elution method to identify unknowns in the sample. An external reference standard of 
Leucine enkephalin was infused in order to confirm mass accuracy of the Mass Spectrometre (MS) data 
acquired. The samples were run in triplicate to ensure consistency and data were analysed by Masslynx 
4.1 software. HPLC conditions: A waters Alliance 2695 with a 2996 Photodiode Array detector and 
Waters Xbridge C18 5 μ m 150 × 4.6 mm was used for the chromatographic separation with mobile phase: 
Acetonitrile (containing 0.1% formic acid) and Water (containing 0.1% formic acid) using the following 
gradient: 0 min (10:90); 0.5 min (10:90); 5 min (90:10); 10 min (100:0); 11 min (100:0); 11.1 min (10:90); 
14 min (10:90). A flow rate of 0.5 ml/min, sample run time of 14 min and injection volume of 1–30 μ l 
was used. For CB1954 the following gradient was used: 0 min (10:90); 0.5 min (10:90); 26 min (30:70); 
27 min (10:90); 30 min (10:90). A flow rate of 1 ml/min, sample run time of 30 min and injection volume 
of 10 μ l was used. The MS conditions were as follows: the samples were subjected to ESI + ionisation 
and acquired from 90 to 1250 m/z at a capillary voltage of 3.00 kV, sample cone of 30 V and a source 
temperature of 140 °C. An external Enkephalin in Water/Acetonitrile (ESI + m/z = 556.2771) for exact 
mass correction using Lockspray was used. The UV conditions were set at a sampling rate of 1 spectrum/
second, scanning wavelengths from 195–400 nm at a resolution of 1.2 nm.
Murine experiments. All animal procedures were performed according to the national ethical guidelines 
of the Health Products Regulatory Authority (HPRA). Protocols were approved by the University College 
Cork Animal Experimentation Ethics Committee (AERR #2010/003 and #2012/015).
Animals and Tumour Induction. Mice were kept at a constant room temperature (22 °C) with a natural 
day/night light cycle in a conventional animal colony. Standard laboratory food and water were provided 
ad libitum. Before experiments, the mice were afforded an adaptation period of at least 7 days. Female 
mice in good condition, without fungal or other infections, weighing 16–22 g and of 6–8 weeks of age, 
were included in experiments (Harlan, Oxfordshire, UK). At experiment end, animals were euthanised 
by cervical dislocation. For CT26 tumour induction, 6 × 105 cells suspended in 200 μ l of serum-free 
culture medium were injected subcutaneously (s.c.) into the flank. The viability of cells used for inoc-
ulation was greater than 95% as determined by visual count using a haemocytometer and Trypan Blue 
Dye Exclusion (Gibco), or the Nucleocounter system (ChemoMetec, Bioimages Ltd, Cavan, Ireland). 
Following tumour establishment, tumours were allowed to grow and develop and were monitored three 
times weekly. Tumour volume was calculated according to the formula V = (ab2) Π /6, where a is the 
longest diameter of the tumour and b is the longest diameter perpendicular to diameter a. When tumours 
reached approximately 100 mm3 in volume, mice were randomly divided into experimental groups.
Bacterial and drug administration. Overnight cultures of E. coli were re-inoculated into fresh LB (1/50 
dilution) and incubated shaking at 37 oC until they reached an OD600 of 0.7. Cells were then washed 
twice in PBS. Tumours were administered 106 E. coli in an injection volume of 50 μ l by intratumoral 
(i.t.) injection. The viable count of each inoculum was determined by retrospective plating onto LB agar. 
Two h post bacterial administration, drug (gemcitabine 60 mg/kg or CB1954 20 mg/kg) was administered 
by intra-peritoneal (i.p.) injection in an injection volume of 50 μ l. The drug was subsequently adminis-
tered on days 3, 6, 9, and 11 and animals not receiving drug were administered an equal volume of PBS 
vehicle. For imaging experiments, mice were anesthetized via inhalation of isoflurane (Piramal Critical 
Care, Inc).
Statistical analysis. For bioinformatics, statistical analysis was performed in R. For biological in vitro 
and in vivo assays, two-sided, paired student’s t test with 95% confidence or Mann Whitney U test were 
employed to investigate statistical differences, using GraphPad Prism or Microsoft Excel 12. Multiple 
comparison tests were carried out using the Bonferroni post hoc test. Statistical significance of survival 
between groups in murine experiments was determined using the Log-rank (Mantel-Cox) Test. Survival 
curves are presented as Kaplan-Meier plots.
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